CCRN · Cross Country Healthcare, Inc. · Stock research

Current Thesis

The merger-arb closed out by completion, not by break. The Knox Lane take-private became effective 2026-07-21: each share converted into the right to receive $13.25 in cash, Nasdaq suspended trading before the open that morning, and Nasdaq filed Form 25 the same day to remove the listing; the company stated it intends to file Form 15 to terminate registration and suspend reporting (no date disclosed). Six directors — Kevin C. Clark, W. Larry Cash, Venkat Bhamidipati, Dwayne Allen, Gale Fitzgerald and Janice Nevin — resigned effective 2026-07-21, and Joel Tremblay was appointed CEO of the private entity. The last completed daily close in the graded series is $13.25 on 2026-07-20, the day before suspension. There is no listed security left to price, no earnings date, no filing calendar.

The narrative is dead, dated 2026-07-21. The site's dead label normally covers a failed narrative; here the structure is gone for the arithmetically opposite reason — the binary resolved in favour of completion and the equity was extinguished. Either path produces the same thing for a reader: nothing tradable.

Bullish and bearish views on Cross Country Healthcare, Inc.

The model's bull view on Cross Country Healthcare, Inc. (CCRN), in brief: The deal closed at par, as the spread implied. The bear view: There is no residual equity claim and no way to express a view. Both cases follow in full.

Bull Case

• The deal closed at par, as the spread implied. Consideration was $13.25/share cash, ~$437M, agreed 2026-05-06 at a 31% premium to that day's close, and consummated 2026-07-21. Holders of record on the effective date have a cash claim through the paying agent; unexchanged certificates are an administrative matter, not a market exposure.
• Every gate cleared in sequence. HSR waiting periods for both the merger and the carve-out of the locums business to All Star Healthcare Solutions expired 2026-06-22 with no second request; stockholders adopted the merger agreement on 2026-07-16 with 23,356,105 for, 12,309 against, 10,439 abstentions. The antitrust failure mode that killed the prior Aya Healthcare deal (terminated 2025-12-03, $18.61/share) did not recur with a financial sponsor.
• Equity awards were cashed out at the deal price. Restricted stock fully vested, was cancelled and converted at $13.25; performance awards vested at the greater of target and actual performance and converted at $13.25. The ABL credit agreement dated 2019-10-25 was discharged and terminated concurrently with closing.

None of this is a forward case. It is the settlement record of a situation that is over.

Bear Case

• There is no residual equity claim and no way to express a view. Post-2026-07-21 there is no US-listed common stock, no quote, no float, no borrow. Any CCRN daily bar dated after the suspension is a vendor artifact.
• The private entity is not the pre-deal business. The locums division went to All Star Healthcare Solutions, a Knox Lane portfolio company, at closing. Whatever the remaining workforce-solutions business earns is unobservable once Form 15 suspends reporting.
• The last public fundamentals were contracting. Q1-2026 (reported 2026-05-07): revenue $241.1M, -17.8% YoY against $293.4M; net loss $4.3M, -$0.14 per share. That deterioration is the read-across a listed peer inherits, and it is the last datapoint this company will publish.
• Merger-objection litigation was live into the close — two stockholder suits plus demand letters over proxy disclosure, denied by the company and answered with supplemental DEFA14A disclosures; a plaintiff firm publicly renewed its investigation on 2026-07-15. Post-closing residue of that kind resolves in court, not in a share price.

Setup & Price Structure

• Terminal print: $13.25 on 2026-07-20, exactly the merger consideration. The series stops there; suspension came before the 2026-07-21 open.
• The momentum readings are arithmetic residue, not a live tape. RSI(14) 70.0, three-month return +33.0%, -6.9% from the 52-week high of $14.23 — all of that is the re-rating from roughly $10 pre-announcement to a pinned $13.2x band after 2026-05-06, frozen by the delisting. An RSI reading on a series that ended describes nothing forward.
• The $14.23 52-week high sits above the deal price. Inference, not a filed fact: a print above $13.25 could not occur once the cash agreement was public, so that high belongs to the pre-2026-05-06 tape. No base formed after the announcement and none can now.
• the ownership register had concentrated into deal-completion holders by the 2026-07-16 record, which is the normal end-state of a merger book and the reason the tape carried no two-way flow into the close. There is no upcoming earnings date to crowd into and no insider transactions to watch; management equity was cashed at $13.25 by contract.

Catalyst Calendar (next 30 days)

• None. There is no dated corporate event for the common stock in the window ending 2026-09-15 — no earnings print, no shareholder meeting, no regulatory decision, because reporting obligations were being terminated as of the 2026-07-21 closing.

Elapsed catalysts

• 2026-07-21 (elapsed) — merger effective; Form 25 filed by Nasdaq; trading suspended. This is the event the calendar was built around and it has passed. (passed 36d ago)
• Form 15 filing — no date disclosed. The 2026-07-21 8-K states an intent to file; the company did not publish a date, and no date should be assumed. (passed 36d ago)

What Would Change Our Mind

What would reopen this is a reversal of the closing itself — an appraisal or fraud action unwinding the 2026-07-21 merger, or a re-registration and relisting of the common stock. Neither has been filed or announced, and both are remote enough that the base case is a permanently closed situation. Absent that, the gradeable condition cannot resolve: a daily close below $13.25 will not print, because there is no listed security to produce one. A reader who sees a CCRN daily bar dated after 2026-07-21 on a screen should treat it as stale vendor data and check the Form 25 before acting on it. The one thing that would genuinely change the frame — a listed successor security or a re-IPO of the Knox Lane entity — has no announced timetable.

Correlation Notes

• Healthcare staffing cycle: CCRN's final public quarter (-17.8% YoY revenue, Q1-2026) is a datapoint on post-pandemic travel-nurse bill-rate and volume normalisation. With CCRN private, AMN Healthcare Services is the remaining large listed US pure-play through which that cycle is observable; this dossier asserts no figures for AMN.
• Small-cap take-private flow: the completion at $13.25 (~$437M) is a filed clearing price for a sub-$500M healthcare services asset in mid-2026. It is one observation and supports no conclusion about sponsor appetite for the group.
• Index mechanics (inferred): delisting removes the name from small-cap benchmarks, so any residual index-related flow would have been concentrated around the 2026-07-21 suspension rather than after it.
• No macro linkage remains. A cash-settled, delisted equity has zero beta to rates, hospital utilisation or labour data. Prior correlation framing for this name is obsolete as of 2026-07-21.